The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
 
Morten Mau-Sørensen
No Relationships to Disclose
 
Scott Randall Plotkin
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - AbbVie; Agios; Angiochem; AstraZeneca; Cavion; Celldex; Exelixis; Genentech/Roche; GlaxoSmithKline; Karyopharm Therapeutics; Midatech Pharma; Momenta Pharmaceuticals; Novartis; Novocure; Regeneron; Sanofi; Sigma-Tau; Vascular Biogenics
Speakers' Bureau - Merck
 
Andrew L. Kung
No Relationships to Disclose
 
Ulrik Niels Lassen
No Relationships to Disclose
 
Jean-Richard Saint-Martin
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Greg Wright
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Aleksander Chudnovsky
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Joel Ellis
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Friedlander
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Bert van Eijk
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Michael G. Kauffman
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Andrew B. Lassman
Consulting or Advisory Role - Abbvie; Celgene; Cortice Biosciences; Foundation Medicine; Genentech/Roche; HERON; Midatech Pharma; Novartis; Oxigene; Regeneron
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); e-Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); ImmunoCellular Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Novocure (Inst); Novocure (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Stemline Therapeutics (Inst); Tocagen (Inst); VBL Therapeutics (Inst)